intestinal absorption of glucose Inhibitors
1 drugsAbout intestinal absorption of glucose
Intestinal absorption of glucose is a key physiological process involving glucose uptake from the small intestine into the bloodstream. This process is tightly regulated and can become dysregulated in metabolic disorders like diabetes, impacting blood sugar levels.
Modulating intestinal glucose absorption is a therapeutic strategy for managing blood sugar and improving outcomes in metabolic diseases. Currently, there is no genetic evidence directly linking this target to specific diseases.
There is one FDA-approved drug, XIGDUO XR (AstraZeneca), targeting intestinal glucose absorption for metabolic indications. This drug is a small molecule, representing 100% of the modality landscape for this target.
Strategic Insights
ℹ️ How we calculate- Validated target with strong trial activity and 82% attractiveness score.
- White space opportunity in Albuminuria with only 4 trials.
Top intestinal absorption of glucose Drugs
AstraZeneca is the only company with an approved drug targeting intestinal glucose absorption.
The market is highly concentrated, presenting a high barrier to entry unless a differentiated product can be developed.
intestinal absorption of glucose Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets intestinal absorption of glucose, using small molecule modality.
Explore alternative modalities like antibodies or peptides to differentiate from existing therapies and potentially improve efficacy.
intestinal absorption of glucose Clinical Trials 403 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 65 | 48 | 4 | 13 | 92% |
| Phase 2 | 88 | 41 | 12 | 34 | 77% |
| Phase 3 | 113 | 67 | 3 | 41 | 96% |
| Phase 4 | 137 | 86 | 13 | 35 | 87% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
2 Phase 3 trials testing approved intestinal absorption of glucose drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting intestinal absorption of glucose. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
intestinal absorption of glucose Drug Approval Timeline (2014 - 2014)
The first and only drug, XIGDUO XR, was approved in 2014.
The approval timeline indicates a potentially unsaturated market, but also a lack of recent innovation in this area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 9 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 352 clinical trials targeting intestinal absorption of glucose.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities